Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280118 | 0.94 | TSHR (0.30) | TSHR | |
| Zinc Ion SCHEMBL16280156 | 0.94 | TSHR (0.30) | TSHR | |
| SCHEMBL16279710 | 0.94 | TSHR (0.30) | TSHR | |
| SCHEMBL15939040 | 0.78 | — | — | |
| SCHEMBL7654 | 0.75 | — | — | |
| SCHEMBL7755370 | 0.75 | TSHR (0.46) | TSHR | |
| SCHEMBL4447506 | 0.73 | — | — | |
| Ammonia Solution, Strong SCHEMBL3287565 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL1899233 | 0.71 | — | — | |
| SCHEMBL17491167 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708538-B2 | Flame protection agent compositions containing triazine intercalated metal phosphates | J.M. HUBER CORPORATION (US) | 2017-07-18 | — | — | US | claimed |
| US-20140361230-A1 | FLAME PROTECTION AGENT COMPOSITIONS CONTAINING TRIAZINE INTERCALATED METAL PHOSPHATES | J.M. HUBER CORPORATION | 2014-12-11 | — | — | US | claimed |
| US-10351776-B2 | Triazine-intercalated metal phosphates, compositions, and methods | J.M. HUBER CORPORATION (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170349835-A1 | Triazine-Intercalated Metal Phosphates, Compositions, and Methods | HUBER CORP J M (US) | 2017-12-07 | — | — | US | disclosed |
| US-9708538-B2 | Flame protection agent compositions containing triazine intercalated metal phosphates | J.M. HUBER CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140361230-A1 | FLAME PROTECTION AGENT COMPOSITIONS CONTAINING TRIAZINE INTERCALATED METAL PHOSPHATES | J.M. HUBER CORPORATION | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140361230-A1 | FLAME PROTECTION AGENT COMPOSITIONS CONTAINING TRIAZINE INTERCALATED METAL PHOSPHATES | AP3M1, AFF2, AFF4 | TSHR 1879/4885 |
| US-20170349835-A1 | Triazine-Intercalated Metal Phosphates, Compositions, and Methods | AP3M1, IPO4, HAX1 | TSHR 2548/4885 |
| US-10351776-B2 | Triazine-intercalated metal phosphates, compositions, and methods | IPO4, AP3M1, PPIP5K2 | TSHR 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.